Controversies in Allergy: The potential role of biologics as first line therapy in eosinophilic disorders.

Dellon, Evan S; Simon, Dagmar; Wechsler, Michael E (2022). Controversies in Allergy: The potential role of biologics as first line therapy in eosinophilic disorders. The journal of allergy and clinical immunology. In practice, 10(5), pp. 1169-1176. Elsevier 10.1016/j.jaip.2022.01.043

Preview

Text 1-s2.0-S2213219822001283-main.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

With advances in understanding the role of eosinophils in disease pathogenesis, particularly in the airways, gastrointestinal (GI) tract, and skin, targeting eosinophils or the cytokines that lead to their production, activation, and survival has become an increasingly pursued therapeutic approach. Newly developed biologic agents target eosinophils directly, other cells interacting with or activating eosinophils, or cytokines in the Type 2 inflammatory pathway with specific antibodies. Current treatment paradigms reserve therapy with biologics for patients refractory to or intolerant of corticosteroids or immunosuppressants. Given accumulating data for safety and efficacy of these biologics, however, there is the question of whether targeted treatments should be used earlier in the treatment algorithm. In this article, we discuss the pros and cons of using biologics as first-line therapy for eosinophilic diseases of the airways, GI tract, and skin. We highlight emerging biologic agents and future directions for research, as well as a rationale for the early use of some biologics to prevent tissue damage, disease progression, and organ dysfunction in selected conditions.

Interest & Impact

Downloads

118 since deposited on 21 Feb 2022
51 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item